Teva Pharmaceutical Industries Ltd
NYSE:TEVA
Teva Pharmaceutical Industries Ltd
Revenue
Teva Pharmaceutical Industries Ltd
Revenue Peer Comparison
Competitive Revenue Analysis
Latest Figures & CAGR of Competitors
Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
T
|
Teva Pharmaceutical Industries Ltd
TASE:TEVA
|
Revenue
$15.8B
|
CAGR 3-Years
-2%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
-2%
|
Taro Pharmaceutical Industries Ltd
NYSE:TARO
|
Revenue
$610.8m
|
CAGR 3-Years
2%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
-2%
|
|
I
|
InterCure Ltd
TASE:INCR
|
Revenue
₪414.8m
|
CAGR 3-Years
164%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
48%
|
Mediwound Ltd
NASDAQ:MDWD
|
Revenue
$18.7m
|
CAGR 3-Years
-5%
|
CAGR 5-Years
41%
|
CAGR 10-Years
N/A
|
|
R
|
Rekah Pharmaceutical Industry Ltd
TASE:REKA
|
Revenue
₪315.3m
|
CAGR 3-Years
10%
|
CAGR 5-Years
9%
|
CAGR 10-Years
1%
|
C
|
Cannassure Therapeutics Ltd
TASE:CSURE
|
Revenue
₪33.8m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
Teva Pharmaceutical Industries Ltd
Revenue Breakdown
Breakdown by Geography
Teva Pharmaceutical Industries Ltd
Breakdown by Segments
Teva Pharmaceutical Industries Ltd
Total Revenue:
15.8B
USD
|
Product:
12.8B
USD
|
North America Segment:
7.5B
USD
|
Europe Segment:
4.5B
USD
|
International Markets:
1.9B
USD
|
Generics Medicians:
1.6B
USD
|
Distribution Service:
1.5B
USD
|
Anda:
1.5B
USD
|
Other Activities:
1B
USD
|
Austedo:
963m
USD
|
Product And Service, Other:
428m
USD
|
Bendeka And Treanda:
316m
USD
|
Respiratory Product:
273m
USD
|
Other Products:
246m
USD
|
License:
212m
USD
|
Copaxone:
36m
USD
|
Ajovy:
35m
USD
|
See Also
What is Teva Pharmaceutical Industries Ltd's Revenue?
Revenue
15.8B
USD
Based on the financial report for Dec 31, 2023, Teva Pharmaceutical Industries Ltd's Revenue amounts to 15.8B USD.
What is Teva Pharmaceutical Industries Ltd's Revenue growth rate?
Revenue CAGR 10Y
-2%
Over the last year, the Revenue growth was 6%. The average annual Revenue growth rates for Teva Pharmaceutical Industries Ltd have been -2% over the past three years , -3% over the past five years , and -2% over the past ten years .